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Abstract
Introduction—Bisulfite treatment of DNA introduces methylation-dependent sequence changes
through selective chemical conversion of nonmethylated cytosine to uracil and serves as
pretreatment step for the majority of DNA methylation analysis methods.
Methods—We have evaluated the conversion performance of five of the most commonly used
bisulfite treatment kits [MethylDetector (Active Motif), Epitect+ (Qiagen), Zymo Methylation,
Zymo Gold and Zymo Lightning (all from Zymo Research)] by pyrosequencing four different
regions with variable methylation levels, including: a repetitive element (ALUSX), a gene with low
levels of methylation (IL6ST), an imprinted gene expected to be approximately 50% methylated
(IGF2), and a fully methylated gene (ST3GAL2). In addition, we have studied the influence of
duration (3 vs. 16 h) and type (fixed temperature vs. cycling program) of incubation protocol on
the conversion efficiency of each evaluated kit.
Results—All kits produced similar conversion rates of ALUSX, IGF2 and ST3GAL2, while the
conversion of the low methylated IL6ST gene was variable between kits. The Zymo kits were
highly consistent in their performance even when different protocols of incubation were applied,
generating full conversion at the low methylated gene IL6; this was not true for the
MethylDetector and Epitect+ kits. However, long-cycling incubation could produce similar
conversion rates for the same locus in combination with Active Motif and Qiagen kits.
Conclusions—The selection of a long-cycling protocol during conversion permits
standardization of protocols, improving the reproducibility of methylation estimates across
laboratories for gene-specific, genome-wide and bisulfite-based sequencing analyses.
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Introduction
DNA methylation is an important molecular mechanism regulating several biological
processes, such as genomic imprinting, X-inactivation, and tissue-specific gene expression.
Since its original identification as an epigenetic regulator, numerous assays have been
developed to study cytosine methylation, including methylation-sensitive restriction enzyme
mapping, deamination of unmethylated cytosines with sodium bisulfite, and enrichment with
targeting antibodies [1, 2]. In the last 10 years, profiling and fingerprinting the human
methylome has become increasingly focused on developing methodologies that enable
single base pair resolution due to the observed functional consequences of both regional and
single CpG site methylation changes [3-6].
Most of these methods rely on bisulfite conversion of genomic DNA. Introduced in 1970 by
Hayatsu and colleagues [7, 8], bisulfite treatment opened new possibilities in the field of the
DNA methylation study by providing a means to quantitatively assess site-specific
methylation [9], Bisulfite treatment deaminates cytosine to uracil and leaves 5-
methylcytosine unchanged [9,10], enabling estimation of the average methylation level as
the proportion of cytosines in a given DNA sequence. However, a number of problems can
arise during bisulfite treatment of genomic DNA that lead to incorrect conversion of the
unmethylated cytosines. Failed conversion occurs when an unmethylated cytosine is not
deaminated, resulting in false methylation detection [11], This can inflate estimations of
methylation densities, and can typically be reduced both by increasing the duration of
bisulfite treatment [12] or the number of denaturation steps used during conversion [13, 14],
Inappropriate conversion occurs instead when a methylated cytosine is deaminated to
thymine, the reasons for which remain unknown [11,12,15].
Many DNA bisulfite treatment kits are now available on the market. However, each kit
proposes different protocols and conditions that may lead to different efficiency and
accuracy of DNA conversion. The main differences reside in the duration (from 1 to 16 h)
and type (fixed vs. cycling protocol) of incubation during the desulfonation step of the
reaction. We evaluated the bisulfite conversion performance of five different commercially
available kits by pyrosequencing a set of genes with variable expected DNA methylation
status. In addition, we studied the influence of duration and type of incubation protocol on
the conversion efficiency of each evaluated kit.
Materials and Methods
Genomic DNA was extracted from whole blood of two anonymous healthy Caucasian male
donors (individuals A and B, aged between 40–50 years) by using the Gentra Puregene
Blood Kit (Qiagen) according to the manufacturer’s protocol. DNA bisulfite treatment was
performed using the MethylDetector (Active Motif), Epitect+ (Qiagen), Zymo Methylation,
Zymo Gold, and the Zymo Lightning (all from Zymo Research) kits according to their
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respective manufacturer’s instructions. In addition, three different incubation protocols
(‘cycling 16 h’, ‘cycling 8 h’ and ‘fixed 3 h’) were used to test the performance of the
MethylDetector, Epitect+ and Zymo Gold kits. The evaluated kits and protocols are
summarized in table 1. Each incubation protocol was tested in duplicate, and for each
sample of bisulfite-treated DNA, two PCR replicates were performed. All bisulfite
conversions were undertaken on the same thermo-cycler. After bisulfite treatment, all
samples were immediately stored at −20°C and simultaneously analyzed by pyrosequencing
in a second phase of the study.
Four different regions were pyrosequenced to assess the bisulfite conversion of DNA
methylation: ALUSX (a repetitive element), IL6ST (low methylated gene), IGF2 (imprinted
gene with expected 50% methylation), and ST3GAL2 (fully methylated gene), IL6ST and
ST3GAL2 were selected from an existing Illumina Infinium 450K study performed on blood
buffy coat genomic DNA from a sample of healthy individuals.ALUSX [16] and IGF2 [17,
18] pyrosequencing assays have been described previously. New methylation assays were
designed for IL6ST and ST3GAL2 using the PyroMark Assay Design Software 2.0
(www.qiagen.com). The locations of the amplicons are described in table 2. The IL6ST and
ST3GAL2 assays were validated with a DNA methylation scale (from 0 to 100%), which
was created from whole-genome amplified DNA (hypomethylated DNA), and DNA treated
with CpG methyl-transferase M.SssI (hypermethylated DNA; New England Biolabs,
Ipswich, Mass., USA), The methylation scales were tested in duplicate for each assay as
described [18, 19]. Each assay included a bisulfite conversion check to verify full
conversion of the DNA. Methylation levels for all CpG sites were assessed using the
Pyromark Q24 pyrosequencer (Qiagen). The reported methylation levels are the average of
two distinct bisulfite treatments performed for each of the protocol and kit combination.
Replicates had an SD below 5%.
Results
All analyses were performed using blood samples from two healthy male individuals. The
patterns of methylation variation induced by the kit protocol were similar between the
individuals. For this reason, methylation levels are only displayed for one individual, with
the findings for the second reported in the online supplementary information (for all online
suppl. material, see www.karger.com/doi/10.1159/000358882).
We first evaluated the bisulfite conversion performance of MethylDetector, Epitect+, Zymo
Methylation and Zymo Gold by processing the samples according to the manufacturer’s
instructions. While the methylation levels of ALUSX, IGF2 and ST3GAL2 were relatively
constant across the kits, the methylation level of the hypomethylated IL6ST was more
variable at certain CpG sites (CpG site 4 and 9, fig. 1), The methylation levels estimated
using the Zymo Methylation and Gold kits were comparable, while MethylDetector and
Epitect+ produced apparent incomplete conversion at IL6ST CpG4 (fig. 1), We also tested
the conversion efficiency of Zymo Lightning for the same regions and compared it with the
performance of both Zymo Methylation and Zymo Gold. Zymo Lightning is a recently
released fast bisulfite treatment option. According to the manufacturers’ protocol, efficient
conversion of cytosines can be achieved after an incubation protocol of 1 h and 8 min,
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dramatically reducing the time of the bisulfite-treated DNA sample preparation. The
methylation level of each gene was similar across the three Zymo kits (fig. 1).
Four of the kits tested (Epitect+, MethylDetector, Zymo Gold and Zymo Methylation) differ
with respect to their conversion/incubation protocol. To assess the potential impact of the
incubation protocol, we tested two different incubation sequences of temperatures for each
kit. The first protocol, designated as ‘cycling 16 h’ is recommended by the Zymo
Methylation kit manufacturer instructions to be used when performing Illumina Infinium
450K array analysis. It consists of 16 cycles of 95°C for 30 s, 50°C for 1 h, and
subsequently holding the temperature constant at 4°C. The second protocol, ‘cycling 8 h’,
was custom designed to evaluate the impact of a shorter cycling protocol on the cytosine
conversion. The custom protocol consists of eight cycles of 95°C for 6 min, 60°C for 30 min
and subsequently holding the temperature at4°C. The ‘cycling 16 h’ incubation generated
more efficient conversion for all four kits tested at the IL6ST locus. When using the
MethylDetector kit from Active Motif (fig. 2), IL6ST CpG4 methylation was ten times lower
after the application of the ‘cycling 16 h’ incubation protocol (fig. 3), Smaller differences,
following a similar trend, were observed for the Zymo and Epitect+ kits (fig. 3), No
differences were observed for the other genes studied (data not shown). When applying the
‘cycling 8 h’ protocol, better conversion was achieved for the MethylDetector, the Zymo
Gold and Zymo Methylation kits (with comparable values to the ‘cycling 16 h’ protocol).
The ‘cycling 8 h’ protocol did not increase the cytosine conversion using the Epitect+ kit
(fig. 3).
To confirm that long incubation with cycling (‘cycling 16 h’ protocol) indeed generates the
best conversion efficiency of unmethylated cytosines, we also used a third protocol (‘fixed
T’) for both the Active Motif and Epitect+ kits. This manufacturer’s protocol for the Zymo
Methylation Gold kit consists of incubation at 98°C for 10 min, 64°C for 2.5 h, and a final
holding temperature at 4°C. The Zymo Gold performance according to the manufacturer’s
protocol is shown in figure 1. The ‘fixed 3 h’ protocol did not effectively convert cytosines
when using either MethylDetector or Epitect+ kits, with higher variability in the methylation
values detected across the four regions included in this study (fig. 2).
Discussion
Most technologies used for DNA methylation analyses rely on bisulfite treatment of DNA,
which introduces methylation-dependent sequence changes through selective chemical
conversion of nonmethylated cytosine to uracil. Currently, a number of commercial kits are
available for bisulfite conversion.
We evaluated the conversion performance of four of the most commonly used bisulfite
treatment kits (MethylDetector, Epitect+, Zymo Methylation, and Zymo Gold) and the
recently released fast bisulfite kit from Zymo (Zymo Lightning) by pyrosequencing four
candidate regions with different methylation values. These regions included a repetitive
element (ALUSX), a low methylated gene (IL6ST) , an imprinted gene with expected
methylation values around 50% (IGF2) and a fully methylated gene (ST3GAL2). Generally,
all kits have been designed to ensure minimal DNA degradation during conversion and
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minimal DNA loss during purification to avoid low DNA yield, highly fragmented DNA,
and irreproducible conversion rates. Sulfonation and cytosine deamination for all kits used
in this study occur during DNA incubation with the respective conversion reagents, while
desulfonation occurs in on-column steps that include DNA purification as well. However,
some differences in reagents and sample preparation protocol exist and might result in
different conversion rates. There are several differences in the material prescribed in the
protocols between kits. These include specific buffers, such as the ‘DNA Protect Buffer’ in
the Epitect+ kit that contains a pH indicator dye as a mixing control in the setup of the
reaction, allowing confirmation of the correct pH necessary for cytosine conversion. Unlike
Zymo Gold and Epitect+, the MethylDetector and Zymo Methylation protocols separate the
alkaline/denaturation step from the conversion step itself. Additionally, Epitect+ and
MethylDetector utilize flat filters for the on-column steps, while Zymo kits utilize a conical
filter. Active Motif provides a positive PCR control in its MethylDetector kit, which
amplifies a specific region of the pl6 locus on chromosome 9 to check for conversion of the
DNA samples.
Grunau et al. [12] observed that at a given bisulfite concentration, the reaction kinetics of the
conversion of cytosine to uracil are nonlinear and depend on the reaction temperature and
the reaction time. Accordingly, we found that the variability of the conversion reaction is
associated with incubation duration (short vs. longtime) and type (fixed vs. cycling
program). Despite their differences, all Zymo kits were highly consistent in their
performance, even when different protocols of incubation were applied (fig. 1, 2), We
observed similar conversion efficiency for IL6ST, for which we expected to see higher
variability, when applying a long-cycling incubation to the MethylDetector and Epitect+ kits
(fig. 3), When using each of the manufacturer-recommended protocols, we did not observe
the same conversion rate (fig. 1), A short incubation program (‘fixed 3 h’ protocol) at a
fixed temperature confirmed the latter finding, as it generated highly variable methylation
results across all regions studied (fig. 2).
Performing a reproducible bisulfite conversion reaction is necessary for both genome-wide
and gene-specific DNA methylation studies. Particularly, genome-wide data need to be
comparable among laboratories to integrate studies or validate DNA methylation findings
[6], At the moment, several tools and techniques are available to assess genome-wide DNA
methylation levels; two in particular, reduced representation of bisulfite sequencing [20, 21]
and the Infinium Human Methylation 450 Bead Chip Array [22, 23], have become
increasingly popular due to their ability to deliver site-specific detail with a relatively high
sensitivity. However, different bisulfite treatment kits are often used for these two methods
(Epitect+ and Zymo Methylation, respectively) [21,23,24] with different incubation duration
and type during conversion. Epigenome-wide association studies using reduced
representation of bisulfite sequencing or the 450K Bead Chip have reported small but
significant methylation differences between the groups that are comparable in magnitude to
the variability observed among the kits used in our study for the low methylated IL6ST
region [6], Increased technical variation among hypomethylated regions decreases our
ability to identify significant changes in these distinct genomic contexts that may have
biologically relevant regulation. Accurate and precise methylation estimates are also
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required for candidate gene studies. Genomic imprinting-dependent DNA methylation [17,
25] and stochastic epigenetic variability observed in cancer [26-28] are quantitative traits
and require reproducible assays given their possible application as diagnostic and/or
prognostic markers. Small differences in methylation have been reported to impact gene
expression [29].
In conclusion, we have compared the performance of five commercially available bisulfite
treatment kits by pyrosequencing regions representative of different methylation levels and
genomic context. Our results suggest that duration (short vs. long) and type (fixed
temperature vs. cycling) of DNA incubation can impact the conversion reaction. While
variability of conversion was observed among kits from different manufacturers, all three
Zymo kits tested produced consistent bisulfite conversion across all genes analyzed.
Using a long-cycling protocol during conversion may provide a means of standardizing
bisulfite treatment of genomic DNA across different laboratories and bisulfite kits, and their
subsequent application in gene-specific analysis, genome-wide arrays and bisulfite-based
sequencing methodologies.
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Fig. 1.
Performance of Active Motif, Epitect+, Zymo Methylation, Zymo Gold and Zymo
Lightning kits according to the respective manufacturer’s protocols (individual A). ALUSX,
IGF2, IL6ST and ST3GAL2 methylation (%) estimates assessed on human whole-blood
DNA from individual A using the Epitect+, MethylDetector, Zymo Gold, Zymo Lightning
and Zymo Methylation kits according to the manufacturer’s protocols. Data are reported as
mean of two different bisulfite treatments after which two technical replicates have been
performed (SD across bisulfite and technical replicates was <5% for each of the CpG sites
analyzed).
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Fig. 2.
Effect of the fixed/short incubation protocols on conversion efficiency (individual A),
ALUSX, IGF2, IL6ST and ST3GAL2 methylation (%) estimates assessed on human whole-
blood DNA from individual A using the Epitect+, MethylDetector and Zymo Gold kits
according to the manufacturer’s protocols, respectively, or by applying the ‘fixed 3 h’
incubation protocol (see table 1), Data are reported as mean of two different bisulfite
treatments after which two technical replicates have been performed (SD across bisulfite and
technical replicates was <5% for each of the CpG sites analyzed).
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Fig. 3.
Effect of the cycling incubation protocols on conversion efficiency for IL6ST methylation
(individual A), Comparison of different DNA incubation protocols (‘cycling 16 h’, ‘cycling
8 h’ and ‘manufacturer’s’, see table 1) in determining IL6ST methylation (%) estimates
assessed on human whole-blood DNA from individual A using the Epitect+,
MethylDetector, Zymo Gold and Zymo Methylation kits. Data are reported as mean of two
different bisulfite treatments after which two technical replicates have been performed (SD
across bisulfite and technical replicates was <5% for each of the CpG sites analyzed).
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Table 1
Alternative incubation protocols tested to evaluate the performance ofthe bisulfite treatment kits
Name of the protocol Incubation steps
Cycling 16 h 16 cycles of 95° C for 30 s and 50° C for 1 h, hold at 4° C
Cycling 8 h 95°C for 5 s, 60° C for 30 s, 8 cycles of 95° C for 6 s and 60° C for 30 s, hold at 4° C
Fixed 3 h 98°C for l0 s and 64° C for 2 h 40 min, hold at 4° C
All five kits included in this study [Epitect+ (Qiagen], MethylDetector (Active Motif), Zymo Gold, Zymo Methylation and Zymo Lightning (all
three from Zymo Research]] were tested according to the protocol specified by the respective manufacturer for each kit. In addition, the Epitect+,
MethylDetector, Zymo Gold and Zymo Methylation were tested using the protocols herein listed to evaluate the influence of type and duration
ofDNA incubation ontheir performance.
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Table 2
Location and characteristics of pyrosequencing amplicons for ALUSX, IL6ST, IGF2 and ST3GAL2 used inthe
study
Name of
assay
Chromo-
some
Start End No. of
CpGs
analyzed
Forward Reverse Sequencing Biotiny-
lated
Annealing
temperature
ALUSX _ _ _ 6 TTTTTATTAAAAA- CCCAAACTAAAA- AATAACTAAAA- Forward 50° C
TATAAAAATT TACAATAA TTACAAAC
IGF2 11 2169369 2169402 3 TGAGGATGGGTTTTT- TCCTCGATCCACCC- GGGGTGGA- Reverse 56° C
GTTTGGTAT AAAATAATAT GGGTGTA
IL6ST 5 55290797 55290852 9 TGAAGGAGTAGGGA- ACCTCT GCGGAG TGAAGGAGTAGGG- Reverse 54° C
TTTGAAGC AAG GAT CT ATTTGAAGC
ST3GAL2 16 70423257 70432300 5 GGTTTTTTTGTTGGT- CTTACCCCAAAACC- GGGTTTTGG- Reverse 55°C
GTTTATTATGT TCTCCTTACTAAA ATGGGA
Nucleotide position according to the February 2009 human reference sequence (GRCh37/hgl9) produced by the International Human Genome
Sequencing Consortium.
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